The financials
Aurinia Pharmaceuticals Inc. by the numbers
Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $78M in Q1 2026 (quarter ended March 31, 2026), up 24% from the same quarter a year earlier. That came with a gross margin of 92% and net income of $34M (44% of revenue). For the full year FY2025, revenue was $283M (+20% year on year) and net income $287M. Its largest product in 2026-Q2 was License Collaboration And Royalty at $3.8M, 50.1% of the disclosed total, just ahead of Service at 49.9%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $78M | $62M | +24% |
| Gross profit | $71M | $54M | +32% |
| Operating income | $41M | $22M | +90% |
| Net income | $34M | $23M | +47% |
| Diluted EPS | $0.25 | $0.16 | +56% |
| Product | Revenue | Share |
|---|---|---|
| License Collaboration And Royalty | $3.8M | 50% |
| Service | $3.8M | 50% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $7.6M (-7.7%)
Service grew +12% year on yearLicense Collaboration And Royalty +11% year on year
Segment Latestquarter on quarteryear on year
- License Collaboration And Royalty$3.8M$3.8MQoQ -8.1%year on year +11%-8.1%+11%
- Service$3.8M$3.8MQoQ -7.3%year on year +12%-7.3%+12%